NASDAQ:MBX

MBX Biosciences (MBX) Stock Price, News & Analysis

MBX Biosciences logo
$49.55 -3.86 (-7.23%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$48.19 -1.36 (-2.75%)
As of 11/20/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About MBX Biosciences Stock (NASDAQ:MBX)

Advanced

Key Stats

Today's Range
$49.36
▼
$54.43
50-Day Range
$48.46
▼
$63.89
52-Week Range
$26.00
▼
$72.64
Volume
581,888 shs
Average Volume
531,052 shs
Market Capitalization
$2.46 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$87.30
Consensus Rating
Moderate Buy

Company Overview

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for endocrine and metabolic disorders. The company’s research focuses on conditions in which naturally occurring hormones are deficient or do not function adequately.

MBX uses its Precision Endocrine Peptide (PEP) platform to design peptide medicines intended to provide more durable hormone activity. Its lead candidate, MBX 2109, is being developed as a long-acting parathyroid hormone replacement therapy for people with chronic hypoparathyroidism.

Based in Carmel, Indiana, MBX Biosciences is advancing a pipeline of investigational therapies. Its candidates are not approved for commercial use.

AI Generated. May Contain Errors.

MBX Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
63rd Percentile Overall Score

MBX MarketRank™: 
3.13210424175 of 5 stars

MBX Biosciences scored higher than 63% of companies evaluated by MarketBeat, and ranked 296th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MBX Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on 1 strong buy rating, 11 buy ratings, no hold ratings, and 2 sell ratings.

  • Upside Potential

    MBX Biosciences has a consensus price target of $87.30, representing about 76.2% upside from its current price of $49.55.

  • Amount of Analyst Coverage

    MBX Biosciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about MBX Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for MBX Biosciences are expected to decrease in the coming year, from ($3.40) to ($4.20) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MBX Biosciences is -16.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MBX Biosciences is -16.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    MBX Biosciences has a P/B Ratio of 5.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    12.91% of the float of MBX Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    MBX Biosciences has a short interest ratio ("days to cover") of 7.9.
  • Change versus previous month

    Short interest in MBX Biosciences has recently decreased by 3.11%, indicating that investor sentiment is improving.
  • Dividend Yield

    MBX Biosciences does not currently pay a dividend.

  • Dividend Growth

    MBX Biosciences does not have a long track record of dividend growth.

  • News Sentiment

    MBX Biosciences has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for MBX Biosciences this week, compared to 3 articles on an average week.
  • Search Interest

    4 people have searched for MBX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MBX Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $288,361.00 in company stock.

  • Percentage Held by Insiders

    31.09% of the stock of MBX Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    MBX Biosciences has minimal institutional ownership at this time.

  • Read more about MBX Biosciences' insider trading history.
Receive MBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MBX Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MBX Stock News Headlines

MBX Biosciences (MBX) Stock Looks Above Fair Value On Phase 3 Progress
Brokers Issue Forecasts for MBX Biosciences FY2026 Earnings
Get your evenings back
The Instant Scanner delivers the night's qualifying setups with exact buy prices and defined exits, in minutes. No hours of flipping through charts, no second-guessing patterns. It's built for traders who want the result without the ritual: a short list and your evening back. Black Friday price is $7 versus the regular $247. One payment covers a full year, with no re-bills.tc pixel
MBX Biosciences, Inc. (MBX) Receives a Buy from Oppenheimer
MBX Biosciences, Inc. (MBX) Receives a Buy from Oppenheimer
MBX Biosciences (NASDAQ:MBX) CEO Sells 4,893 Shares of Stock
See More Headlines

MBX Stock Analysis - Frequently Asked Questions

MBX Biosciences' stock was trading at $31.54 at the start of the year. Since then, MBX stock has increased by 57.1% and is now trading at $49.55.

MBX Biosciences, Inc. (NASDAQ:MBX) released its quarterly earnings data on Monday, November, 9th. The company reported ($1.29) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by $0.49.

MBX Biosciences (MBX) raised $153 million in an initial public offering on Thursday, September 12th 2024. The company issued 10,200,000 shares at $14.00-$16.00 per share.

MBX Biosciences' top institutional shareholders include State Street Corp (1.73%), Goldman Sachs Group Inc. (0.86%), Candriam S.C.A. (0.58%) and Soleus Capital Management L.P. (0.52%). Insiders that own company stock include Patrick J Heron, Life Sciences X LP Frazier, Edward T Mathers, Carl L Gordon, P Kent Hawryluk, Steven L Hoerter, Ora H Pescovitz and Salomon Azoulay.
View institutional ownership trends
.

Shares of MBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MBX Biosciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Strive (ASST), AST SpaceMobile (ASTS), Celldex Therapeutics (CLDX), Definium Therapeutics (DFTX) and Bloom Energy (BE).

Company Calendar

Last Earnings
11/09/2026
Today
11/21/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:MBX
Previous Symbol
NASDAQ:MBX
CIK
1776111
Fax
N/A
Employees
63
Year Founded
2018

Price Target and Rating

High Price Target
$150.00
Low Price Target
$18.00
Potential Upside/Downside
+76.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.79
Research Coverage
14 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.07)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$86.97 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-34.37%
Return on Assets
-32.72%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
19.58
Quick Ratio
19.58

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.52 per share
Price / Book
5.20

Miscellaneous

Outstanding Shares
49,660,000
Free Float
34,218,000
Market Cap
$2.46 billion
Optionable
Optionable
Beta
0.17

Social Links

7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and Google Cover

Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.

Get This Free Report

This page (NASDAQ:MBX) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners